SynBioBeta Speaker
Aryé Elfenbein
Wildtype
Co-founder
Aryé co-founded Wildtype, a company creating a clean, accessible seafood future using cellular agriculture technologies. Wildtype has developed brewery-like systems to grow seafood directly from cells, without the need for fishing or farming. After regulatory clearance in the US, Wildtype became the first company in the world to commercialize a cultivated seafood, starting with salmon. Aryé earned his MD and PhD at Dartmouth and Kyoto University; he completed clinical training in Internal Medicine and Cardiology at Yale. Prior to co-founding Wildtype, Aryé completed a fellowship in cardiovascular regenerative medicine at The Gladstone Institutes / UCSF. A classically-trained cardiologist and musician, Aryé often spends nights practicing in the ICU and piano room.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Aryé
This Year
•
-
Planetary Health
From Feedstock to Fork: De-Risking Bio-Based Foods at Industrial Scale
Bio-based food innovation rarely fails in the lab. It fails in the transition to scale. Between pilot success and commercial launch lie the hardest problems in food: reliable feedstocks, waste stream integration, regulatory approval, capital intensity, and infrastructure built for yesterday’s products. This session brings together leaders across law, industrial food systems, waste valorization, and next-generation proteins to examine what it actually takes to move biological food innovations from concept to shelf. Panelists will explore where risk truly accumulates in bio-based food development, how incumbents and startups navigate scale differently, and why waste streams, compliance strategy, and supply chain design often matter more than the underlying biology. The result is a grounded conversation about what survives real-world constraints, not just what sounds compelling on paper.
Get a Ticket
•
-
Planetary Health
From Feedstock to Fork: De-Risking Bio-Based Foods at Industrial Scale
Bio-based food innovation rarely fails in the lab. It fails in the transition to scale. Between pilot success and commercial launch lie the hardest problems in food: reliable feedstocks, waste stream integration, regulatory approval, capital intensity, and infrastructure built for yesterday’s products. This session brings together leaders across law, industrial food systems, waste valorization, and next-generation proteins to examine what it actually takes to move biological food innovations from concept to shelf. Panelists will explore where risk truly accumulates in bio-based food development, how incumbents and startups navigate scale differently, and why waste streams, compliance strategy, and supply chain design often matter more than the underlying biology. The result is a grounded conversation about what survives real-world constraints, not just what sounds compelling on paper.
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
